MYRIEL, INC.

Saint Paul, MN · Biotech · Private

Brain-penetrant Casp2 inhibitor prodrugs for treating Alzheimer's disease and tauopathies

Grants
$700K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Prodrugs of potent and selective protease inhibitors as tauopathy therapeutics$349,992
Federal grantDepartment of Health and Human Services · Phase I · Prodrugs of potent and selective protease inhibitors as tauopathy therapeutics$349,992
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3125ASDDR, LLC——
3126ThirdLaw Technologies LLC——
3127AVANTYX, LLC——
3128MYRIEL, INC.——
3129MABSWITCH, INC.——
3130KINEA BIO, INC.——
3131nChroma Bio——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.